Cochrane review of dihydroartemisinin-piperaquine for treating uncomplicated malaria

January 21, 2014, Liverpool School of Tropical Medicine

'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' concludes a systematic review published by the Cochrane Infectious Disease Group, hosted by LSTM.

Dihydroartemisinin-piperaquine is one of five artemisinin-based combination therapies currently recommended by the World Health Organization (WHO), and this finds that it is also one of the most studied. The team of authors from South Africa, Kenya, Geneva and Liverpool included 27 randomized studies, enrolling 16,382 adults and children, which directly compared the relative efficacy and safety of dihydroartemisinin-piperaquine and the widely used alternatives; artemether-lumefantrine, plus mefloquine, and artesunate plus amodiaquine.

"The very long duration of action of piperaquine in this combination, means that DHA-P reduces the risk of the person suffering another bout of malaria for up to nine weeks after treatment", explained David Sinclair from LSTM. "This gives it an advantage over most of the other combinations. Mefloquine has a similarly long duration of action but commonly causes such as nausea, vomiting and dizziness."

Dihydroartemisinin-piperaquine also became one of the few antimalarials to be formally registered by a stringent regulatory authority when the European Medicines Agency approved it for use in 2013. The registration process highlighted concerns that dihydroartemisinin-piperaquine caused some short term changes in electrocardiographs tracing the conduction of the heart rhythm. The review also examined this effect, and the authors report that the number of people affected by these changes is small and all resolved spontaneously without serious consequences.

Explore further: Malaria treatment could improve in children

More information: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria, Babalwa Zani, Michael Gathu, Sarah Donegan, Piero L Olliaro and David Sinclair. Published Online: 20 JAN 2014. onlinelibrary.wiley.com/doi/10 … 58.CD010927/abstract

Related Stories

Malaria treatment could improve in children

December 3, 2013
An analysis of patients from across the malaria endemic world suggests that a key antimalarial treatment could be improved by better dosing in young children.

New combination malaria treatment equally effective

April 5, 2012
(HealthDay) -- Fixed-dose, combination pyronaridine-artesunate treatment is as effective as mefloquine plus artesunate in treating malaria infection, according to a study published in the April 5 issue of the New England ...

Recommended for you

Nanoparticle vaccine offers universal protection against influenza A viruses, study finds

January 24, 2018
Researchers have developed a universal vaccine to combat influenza A viruses that produces long-lasting immunity in mice and protects them against the limitations of seasonal flu vaccines, according to a study led by Georgia ...

Leprosy's drug resistance and origin revealed by genome analysis

January 24, 2018
Leprosy is an infectious disease with gruesome symptoms. It damages the skin, peripheral nerves, the upper respiratory tract, and the eyes. Despite being curable with multidrug therapy, leprosy still persists in many developing ...

A new theory on reducing cardiovascular disease risk in binge drinkers

January 23, 2018
A new study shows that binge drinkers have increased levels of a biomarker molecule—microRNA-21—that may contribute to poor vascular function.

Flu infection study increases understanding of natural immunity

January 23, 2018
People with higher levels of antibodies against the stem portion of the influenza virus hemagglutinin (HA) protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according ...

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.